Voriconazole: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CONITEC (Brazil), HAS (France) and PHARMAC (New Zealand), among others, recommended or restricted voriconazole, while AWMSG (Wales) did not recommend it.
The file has been open for more than a decade: 20.3 years separate the first record, 11 May 2004 at TLV (Sweden), from the most recent, 10 Sep 2024 at PHARMAC (New Zealand).
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for voriconazole, 1 submission was never made — an outcome set by the company rather than the assessor.
3 distinct indication wordings are recorded for voriconazole by the agencies that label one in English (AWMSG and SMC).
TLV (Sweden) was first to assess voriconazole, on 11 May 2004; CONITEC (Brazil) did not open a file until 28 Jul 2022 — an unusually long tail of 18.2 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 10 years in total.
4 of the 7 agencies here assessed voriconazole more than once, HAS (France) most often at 11 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for voriconazole.
The full ledger for voriconazole reads 15 recommended, 2 advice, 1 non-submission and 1 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 10 Sep 2024 | Prophylaxis of invasive fungal infections in people with high risk malignancies, lung and liver transplant recipients | funding application decided · decision reached | source |
| CONITEC (Brazil) | 28 Jul 2022 | Tratamento de pacientes com aspergilose invasiva. | incorporated into SUS | source |
| HAS (France) | 5 Feb 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| SMC (Scotland) | 10 Nov 2014 | Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. | not recommended | source |
| AWMSG (Wales) | 31 Oct 2014 | For use as prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant recipien… | not endorsed (non-submission) | source |
15 further decisions for voriconazole, across 5 agencies, are not shown here. They link to 13 further source documents.
Related molecules
- posaconazole — same ATC class J02A — Antimycotics
- caspofungin — same ATC class J02A — Antimycotics
- isavuconazole — same ATC class J02A — Antimycotics
- anidulafungin — same ATC class J02A — Antimycotics
- micafungin — same ATC class J02A — Antimycotics
- dexamethasone — also decided by PHARMAC in 2024Q3
Coverage: 20 decisions for voriconazole from 7 agencies, 2004 to 2024. Data to 7 Sep 2026. ATC class J02A — Antimycotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.